Radiopharmaceutical design

The full exploitation of the wide range of oxidation states of rhenium in radiopharmaceutical design requires not only a wide range of ligand donor types with varied n-donor and acceptor properties, but also suitable reducing agents to provide access to oxidation levels below (VII). This is because for radiopharmaceutical purposes the most conveniently man-factured form of rhenium radionuclides is perrhenate. The traditional routes to reduced rhenium complexes are not particularly amenable to use in a radiopharmaceutical context, where mild, rapid, and preferably... 

In the last decade, a large number of radiolabeled small biomolecules have been studied for their potential as radiopharmaceuticals for diagnosis and radiotherapy of various diseases. This review wiU focus on some fundamental aspects of receptor-based diagnostic radiopharmaceuticals, including radiopharmaceutical design, receptors and receptor imaging, choice of biomolecule, and modification of pharmacokinetics. 

Fig.1. Schematic representation of three approaches in radiopharmaceutical design...

Radiolaria, strontium and barium sulfate biomineralization, 36 169-170 Radiopharmaceuticals, design, 36 25-28 Radiosensitizers, 36 37 Radish white root ferredoxins, 38 231 Radium, binary carbide not reported, 11 210 Radon... 

F. Doiie, Fiuorine-18-iabeiied fiuoropyridines Advances in radiopharmaceutical design, Curr. Pharm. Des. 11 (2005) 3221-3235. 

Fig-1 Schematic presentation of the radiopharmaceutical design. The targeting biomolecule serves as the vehicle to carry a radionuclide to the receptor site on tumor cells. The radionuclide is the radiation source. The bifunctional chelator (BFC) is used for radiometal chelation and attachment of the targeting molecule. The linker is often used for modification of pharmacokinetics. Diethylenetriaminepentaacetic acid (DTPA), 1,4,7,10-tetraaza-cyclododecane-N>N, N">Ar,"-tetraacetic acid (DOTA)... 

Boudreau, R.J. and Efange, S.M. (1992). Computer-Aided Radiopharmaceutical Design. Invest Radiol., 27, 653-658. 

See, e.g., R. DSppen, H. R. Karfunkel, and F. J. J. Leusen,/. Comput. Chem., 11,181 (1990). Computational Chemistry Applied to the Design of Chiral Stationary Phases for Enantiomeric Separation. R. J. Boudeau and S. M. N. Efange, Invest. Radiol., 27, 653 (1992). Computer-Aided Radiopharmaceutical Design. 

DoUe F (2005) Fluorine-18-labeUed fluoropyridines advances in radiopharmaceutical design. CurrPharm Des 11 3221-3235... 

---